Article
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
Molecular cancer - 31 May 2014
Imamura Yu, Lochhead Paul, Yamauchi Mai, Kuchiba Aya, Qian Zhi Rong, Liao Xiaoyun, Nishihara Reiko, Jung Seungyoun, Wu Kana, Nosho Katsuhiko, Wang Yaoyu E, Peng Shouyong, Bass Adam J, Haigis Kevin M, Meyerhardt Jeffrey A, Chan Andrew T, Fuchs Charles S, Ogino Shuji
Abstract excerpt
BACKGROUND: KRAS mutations in codons 12 and 13 are established predictive biomarkers for anti-EGFR therapy in colorectal cancer. Previous studies suggest that KRAS codon 61 and 146 mutations may also predict resistance to anti-EGFR therapy in colorectal cancer. However, clinicopathological, molecular, and prognostic features of colorectal carcinoma with KRAS codon 61 or 146 mutation remain unclear. METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.